Olema Pharmaceuticals Inc
$ 11.80
1.90%
06 Aug - close price
- Market Cap 1,030,700,000 USD
- Current Price $ 11.80
- High / Low $ 12.21 / 11.50
- Stock P/E N/A
- Book Value 5.50
- EPS -2.07
- Next Earning Report 2026-08-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -0.43 %
- 52 Week High 36.26
- 52 Week Low 4.47
About
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company is headquartered in San Francisco, California.
Analyst Target Price
$40.70
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-12 | 2026-03-16 | 2025-11-10 | 2025-08-11 | 2025-05-13 | 2025-03-18 | 2024-11-12 | 2024-08-06 | 2024-05-08 | 2024-03-11 | 2023-11-07 | 2023-08-08 |
| Reported EPS | -0.52 | -0.5044 | -0.49 | -0.51 | -0.36 | -0.51 | -0.6 | -0.54 | -0.56 | -0.49 | -0.48 | -0.49 |
| Estimated EPS | -0.54 | -0.5215 | -0.45 | -0.44 | -0.46 | 0.1732 | -0.57 | -0.54 | -0.55 | -0.48 | -0.51 | -0.71 |
| Surprise | 0.02 | 0.0171 | -0.04 | -0.07 | 0.1 | -0.6832 | -0.03 | 0 | -0.01 | -0.01 | 0.03 | 0.22 |
| Surprise Percentage | 3.7037% | 3.279% | -8.8889% | -15.9091% | 21.7391% | -394.4573% | -5.2632% | 0% | -1.8182% | -2.0833% | 5.8824% | 30.9859% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-10 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.53 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OLMA
2026-08-06 14:39:43
FMR LLC and Abigail P. Johnson have disclosed a 13.8% beneficial ownership stake in Olema Pharmaceuticals Inc. (OLMA) through an Amendment No. 2 to a Schedule 13G filing. This represents 12,075,061.72 shares as of June 30, 2026. FMR LLC holds sole voting power over 12,074,535 shares and both FMR LLC and Abigail Johnson hold sole dispositive power over 12,075,061.72 shares.
2026-08-05 07:39:44
Olema Pharmaceuticals has seen recent insider selling, including a notable divestment by an Independent Director and a larger sale by the Chief Medical Officer last year. While the CMO's sale was at a higher price than current stock, overall insider ownership is modest at 2.7%, and there have been no insider purchases in the last year, leading to caution regarding the stock.
2026-08-04 20:10:11
Olema Oncology has granted stock options to seven new employees, totaling 254,540 shares, effective August 3, 2026. These inducement grants, approved under Olema's 2022 Inducement Plan and in compliance with Nasdaq Listing Rule 5635(c)(4), have an exercise price of $11.28 per share and a 10-year term. The options will vest over four years, with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments, subject to continued employment.
2026-08-04 20:10:11
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) announced that it granted stock options to seven new employees to purchase an aggregate of 254,540 shares of its common stock. These grants were made under the Company's 2022 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options vest over four years, have a 10-year term, and an exercise price of $11.28 per share.
2026-08-03 14:11:36
Olema Pharmaceuticals (OLMA) is scheduled to release its Q2 2026 earnings before market open on Monday, August 10th, with analysts anticipating a loss of $0.53 per share. The company's stock opened at $11.18, down 2.4%, and currently holds a "Moderate Buy" rating with an average analyst price target of $44.10, despite some recent downgrades. Institutional investors hold a significant 91.78% stake in the company, which is advancing its lead therapy candidate, OP-1250, for breast cancer into Phase 3 trials.
2026-08-03 09:11:36
Defilade Capital Management L.P. has increased its stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 21.9%, purchasing an additional 269,902 shares to bring its total to 1.50 million shares valued at approximately $22.4 million. This acquisition makes Olema Pharmaceuticals the 14th largest position in Defilade Capital Management's holdings. Despite some downgrades, analysts generally maintain a "Moderate Buy" rating with an average price target of $44.10 for the clinical-stage biotechnology company, which recently reported a quarterly loss of $0.52 per share, in line with estimates.
